A longitudinal real-life comparison study of natalizumab and fingolimod
A longitudinal real-life comparison study of natalizumab and fingolimod
复制标题
DOI：
10.1111/ane.12718
复制
发表时间：
2017-09-01
影响因子：
3.5
通讯作者：
Morra, V. Brescia
中科院分区：
文献类型：
--
作者：
Lanzillo, R.;Carotenuto, A.;Morra, V. Brescia
背景资料：不同的回顾性研究比较了那他珠单抗和芬戈莫德在复发缓解型多发性硬化症（RRMS）中的作用，结果相互矛盾。我们的目的是探讨处方的态度和两个therapy.Methods的临床结果：我们回顾性地包括所有RRMS患者与那他珠单抗（n= 101）或芬戈莫德（n= 78）作为他们的第一个二线治疗至少24个月的随访。记录人口统计学和临床特征，以计算倾向评分（PS）。关注的结果是年复发率（ARR）、复发风险和EDSS的变化。结果：与芬戈莫德患者相比，在基线时，那他珠单抗患者更年轻，疾病持续时间更短，治疗前1年（1 yR）和2年（2 yR）的复发次数和总体（ARR-PT）复发次数更高。治疗期间，两组复发患者的比例和平均RR相似。然而，那他珠单抗组ARR的变化高于芬戈莫德组（P
Background: Different retrospective studies compared natalizumab and fingolimod in relapsing-remitting multiple sclerosis (RRMS), with conflicting results. We aimed to explore the prescriptive attitude and the clinical outcome of the two therapies.Methods: We retrospectively included all RRMS patients treated with natalizumab (n= 101) or fingolimod (n= 78) as their first second-line therapy with at least 24-month follow-up. Demographic and clinical features were recorded to calculate the propensity score (PS). Outcomes of interest were annualized relapse rate (ARR), risk of relapse, and change in the EDSSResults: At baseline, natalizumab patients were younger and had a shorter disease duration, a higher number of relapse in 1 year (1yR) and 2 years (2yR) and overall (ARR-PT) pretherapy, compared to fingolimod patients. On therapy, the proportion of relapsing patients and the mean RR were similar in the two groups. However, the change in the ARR was higher in natalizumab than in fingolimod group (P